Home > Publications database > Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk. > print

001     180479
005     20240229145620.0
024 7 _ |a 10.1016/j.eclinm.2022.101460
|2 doi
024 7 _ |a pmid:35747198
|2 pmid
024 7 _ |a pmc:PMC9126769
|2 pmc
024 7 _ |a altmetric:128740046
|2 altmetric
037 _ _ |a DKFZ-2022-01358
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Chen, Xuechen
|0 P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9
|b 0
|e First author
|u dkfz
245 _ _ |a Alcohol consumption, polygenic risk score, and early- and late-onset colorectal cancer risk.
260 _ _ |a Amsterdam
|c 2022
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1656326572_4493
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070#LA:C120#
520 _ _ |a Evidence is lacking on the impact of alcohol consumption on colorectal cancer (CRC) risk (overall and by age at diagnosis) by polygenic risk score (PRS) levels, and it is unclear how the magnitude of CRC risk associated with alcohol consumption compares to the magnitude of genetically determined risk.Multiple logistic regression was used to assess the association between alcohol consumption and colorectal cancer (CRC) across PRS levels based on 140 CRC-related loci among 5104 CRC cases and 4131 controls from a large population-based case-control study. We compared the effects for alcohol consumption and PRS on CRC risk using the 'Genetic Risk Equivalent (GRE)' for effective risk communication. Specific analyses were conducted for early-onset CRC (EOCRC, <55 years) and late-onset CRC (LOCRC, ≥55 years).High alcohol consumption, and to a lower extent, also alcohol abstinence were associated with increased CRC risk. Compared to low alcohol consumption (0·1-<25 g/d), lifetime average alcohol consumption ≥25 g/d was more strongly associated with EOCRC [odds ratio (OR) 1·8, 95% confidence interval (CI) 1·2-2·8] than with LOCRC risk (OR 1·3, 95% CI 1·1-1·4) (P-value for interaction with age =0·011). Interactions between alcohol consumption and PRS did not reach statistical significance for either EOCRC or LOCRC risk. The estimated impact of high lifetime alcohol consumption on EOCRC was equivalent to the effect of having 47 percentiles higher PRS (GRE 47, 95% CI 12-82), stronger than the impact on LOCRC (GRE 18, 95% CI 8-29).Excessive alcohol use was strongly associated with EOCRC risk, independent of PRS levels. Abstaining from heavy drinking could reduce risk for CRC, in particular for EOCRC to an extent that would be equivalent to having a much lower genetically determined risk.The first author (X.C.) was supported by the Guangzhou Elite Project (GEP). The DACHS study was supported by grants from the German Research Council (BR 1704/6-1, BR1704/6-3, BR 1704/6-4, BR 1704/6-6, CH 117/1-1, BR 1704/17-1, HO 5117/2-1) and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01GL1712).
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Alcohol consumption
|2 Other
650 _ 7 |a CI, confidence interval
|2 Other
650 _ 7 |a CRC, colorectal cancer
|2 Other
650 _ 7 |a DACHS, Darmkrebs: Chancen der Verhütung durch Screening
|2 Other
650 _ 7 |a EOCRC, early-onset colorectal cancer
|2 Other
650 _ 7 |a Early-onset colorectal cancer
|2 Other
650 _ 7 |a GRE, genetic risk equivalent
|2 Other
650 _ 7 |a GWAS, genome-wide association study
|2 Other
650 _ 7 |a Genetic risk equivalentt
|2 Other
650 _ 7 |a LOCRC, late-onset colorectal cancer
|2 Other
650 _ 7 |a Late-onset colorectal cancer
|2 Other
650 _ 7 |a NSAID, non-steroidal anti-inflammatory drug
|2 Other
650 _ 7 |a OR, odds ratio
|2 Other
650 _ 7 |a PRS, polygenic risk score
|2 Other
650 _ 7 |a Polygenic risk score
|2 Other
650 _ 7 |a SNP, single nucleotide polymorphisms
|2 Other
700 1 _ |a Li, Hengjing
|0 P:(DE-He78)40c45b31a82f8311dd3a7363bd758720
|b 1
|u dkfz
700 1 _ |a Guo, Feng
|0 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919
|b 2
|u dkfz
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 3
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.eclinm.2022.101460
|g Vol. 49, p. 101460 -
|0 PERI:(DE-600)2946413-4
|p 101460
|t EClinicalMedicine
|v 49
|y 2022
|x 2589-5370
909 C O |o oai:inrepo02.dkfz.de:180479
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)40c45b31a82f8311dd3a7363bd758720
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-08-31
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-31
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ECLINICALMEDICINE : 2021
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-26T13:10:03Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-26T13:10:03Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-26T13:10:03Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-10
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b ECLINICALMEDICINE : 2021
|d 2022-11-10
920 2 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 2 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 2
920 0 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21